PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas

Ashley M Cimino-Mathews, Elizabeth Thompson, Janis M Taube, Xiaobu Ye, Yao Lu, Alan Keith Meeker, Haiying Xu, Rajni Sharma, Kristen Lecksell, Toby C. Cornish, Nathan Cuka, Pedram Argani, Leisha A. Emens

Research output: Contribution to journalArticle

Abstract

Programmed death ligand 1 (PD-L1) expression by tumor-infiltrating lymphocytes (TILs) and tumor cells in breast cancer has been reported, but the relationships between PD-L1 expression by TIL, carcinoma cells, and other immunologic features of the breast tumor microenvironment remain unclear. We therefore evaluated the interrelationships between tumor cell surface and TIL PD-L1 expression, lymphocyte subpopulations, and patterns of immune cell infiltration in cohorts of treatment-naive, primary breast cancers (PBCs) (n = 45) and matched PBC and metastatic breast cancers (MBC) (n = 26). Seventy-eight percent of untreated PBCs contained PD-L1+ TILs, but only 21% had PD-L1+ carcinoma cells. Carcinoma PD-L1 expression localized to the tumor invasive front and was associated with high tumor grade (P =.04). Eighty-nine percent of PD-L1+ carcinomas contained brisk TIL infiltrates, compared to only 24% of PD-L1- carcinomas; this included CD3+ (P =.02), CD4+ (P =.04), CD8+ (P =.002), and FoxP3+ T cells (P =.02). PD-L1+ PBCs were more likely to contain PD-L1+ TIL than PD-L1- PBCs (P =.04). Peripheral lymphoid aggregates were present in 100% of PD-L1+ compared to 41% of PD-L1- PBC (P + PBC developed distant recurrence, compared to 15% of patients with PD-L1- PBC. For the matched PBC and MBC cohort, 2 patients (8%) had PD-L1+ tumors, with 1 case concordant and 1 case discordant for carcinoma PD-L1 expression in the PBC and MBC. Our data support PD-L1 expression by tumor cells as a biomarker of active breast tumor immunity and programmed death 1 blockade as a therapeutic strategy for breast cancer.

Original languageEnglish (US)
Pages (from-to)52-63
Number of pages12
JournalHuman Pathology
Volume47
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

CD80 Antigens
Tumor Microenvironment
Breast Neoplasms
Ligands
Tumor-Infiltrating Lymphocytes
Carcinoma
Neoplasms

Keywords

  • Metastatic breast cancer
  • PD-L1
  • Primary breast cancer
  • Tumor infiltrating lymphocytes
  • Tumor microenvironment

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. / Cimino-Mathews, Ashley M; Thompson, Elizabeth; Taube, Janis M; Ye, Xiaobu; Lu, Yao; Meeker, Alan Keith; Xu, Haiying; Sharma, Rajni; Lecksell, Kristen; Cornish, Toby C.; Cuka, Nathan; Argani, Pedram; Emens, Leisha A.

In: Human Pathology, Vol. 47, No. 1, 01.01.2016, p. 52-63.

Research output: Contribution to journalArticle

Cimino-Mathews, Ashley M ; Thompson, Elizabeth ; Taube, Janis M ; Ye, Xiaobu ; Lu, Yao ; Meeker, Alan Keith ; Xu, Haiying ; Sharma, Rajni ; Lecksell, Kristen ; Cornish, Toby C. ; Cuka, Nathan ; Argani, Pedram ; Emens, Leisha A. / PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. In: Human Pathology. 2016 ; Vol. 47, No. 1. pp. 52-63.
@article{1ef5a9ee40854629b6037d4ef1f3c927,
title = "PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas",
abstract = "Programmed death ligand 1 (PD-L1) expression by tumor-infiltrating lymphocytes (TILs) and tumor cells in breast cancer has been reported, but the relationships between PD-L1 expression by TIL, carcinoma cells, and other immunologic features of the breast tumor microenvironment remain unclear. We therefore evaluated the interrelationships between tumor cell surface and TIL PD-L1 expression, lymphocyte subpopulations, and patterns of immune cell infiltration in cohorts of treatment-naive, primary breast cancers (PBCs) (n = 45) and matched PBC and metastatic breast cancers (MBC) (n = 26). Seventy-eight percent of untreated PBCs contained PD-L1+ TILs, but only 21{\%} had PD-L1+ carcinoma cells. Carcinoma PD-L1 expression localized to the tumor invasive front and was associated with high tumor grade (P =.04). Eighty-nine percent of PD-L1+ carcinomas contained brisk TIL infiltrates, compared to only 24{\%} of PD-L1- carcinomas; this included CD3+ (P =.02), CD4+ (P =.04), CD8+ (P =.002), and FoxP3+ T cells (P =.02). PD-L1+ PBCs were more likely to contain PD-L1+ TIL than PD-L1- PBCs (P =.04). Peripheral lymphoid aggregates were present in 100{\%} of PD-L1+ compared to 41{\%} of PD-L1- PBC (P + PBC developed distant recurrence, compared to 15{\%} of patients with PD-L1- PBC. For the matched PBC and MBC cohort, 2 patients (8{\%}) had PD-L1+ tumors, with 1 case concordant and 1 case discordant for carcinoma PD-L1 expression in the PBC and MBC. Our data support PD-L1 expression by tumor cells as a biomarker of active breast tumor immunity and programmed death 1 blockade as a therapeutic strategy for breast cancer.",
keywords = "Metastatic breast cancer, PD-L1, Primary breast cancer, Tumor infiltrating lymphocytes, Tumor microenvironment",
author = "Cimino-Mathews, {Ashley M} and Elizabeth Thompson and Taube, {Janis M} and Xiaobu Ye and Yao Lu and Meeker, {Alan Keith} and Haiying Xu and Rajni Sharma and Kristen Lecksell and Cornish, {Toby C.} and Nathan Cuka and Pedram Argani and Emens, {Leisha A.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.humpath.2015.09.003",
language = "English (US)",
volume = "47",
pages = "52--63",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas

AU - Cimino-Mathews, Ashley M

AU - Thompson, Elizabeth

AU - Taube, Janis M

AU - Ye, Xiaobu

AU - Lu, Yao

AU - Meeker, Alan Keith

AU - Xu, Haiying

AU - Sharma, Rajni

AU - Lecksell, Kristen

AU - Cornish, Toby C.

AU - Cuka, Nathan

AU - Argani, Pedram

AU - Emens, Leisha A.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Programmed death ligand 1 (PD-L1) expression by tumor-infiltrating lymphocytes (TILs) and tumor cells in breast cancer has been reported, but the relationships between PD-L1 expression by TIL, carcinoma cells, and other immunologic features of the breast tumor microenvironment remain unclear. We therefore evaluated the interrelationships between tumor cell surface and TIL PD-L1 expression, lymphocyte subpopulations, and patterns of immune cell infiltration in cohorts of treatment-naive, primary breast cancers (PBCs) (n = 45) and matched PBC and metastatic breast cancers (MBC) (n = 26). Seventy-eight percent of untreated PBCs contained PD-L1+ TILs, but only 21% had PD-L1+ carcinoma cells. Carcinoma PD-L1 expression localized to the tumor invasive front and was associated with high tumor grade (P =.04). Eighty-nine percent of PD-L1+ carcinomas contained brisk TIL infiltrates, compared to only 24% of PD-L1- carcinomas; this included CD3+ (P =.02), CD4+ (P =.04), CD8+ (P =.002), and FoxP3+ T cells (P =.02). PD-L1+ PBCs were more likely to contain PD-L1+ TIL than PD-L1- PBCs (P =.04). Peripheral lymphoid aggregates were present in 100% of PD-L1+ compared to 41% of PD-L1- PBC (P + PBC developed distant recurrence, compared to 15% of patients with PD-L1- PBC. For the matched PBC and MBC cohort, 2 patients (8%) had PD-L1+ tumors, with 1 case concordant and 1 case discordant for carcinoma PD-L1 expression in the PBC and MBC. Our data support PD-L1 expression by tumor cells as a biomarker of active breast tumor immunity and programmed death 1 blockade as a therapeutic strategy for breast cancer.

AB - Programmed death ligand 1 (PD-L1) expression by tumor-infiltrating lymphocytes (TILs) and tumor cells in breast cancer has been reported, but the relationships between PD-L1 expression by TIL, carcinoma cells, and other immunologic features of the breast tumor microenvironment remain unclear. We therefore evaluated the interrelationships between tumor cell surface and TIL PD-L1 expression, lymphocyte subpopulations, and patterns of immune cell infiltration in cohorts of treatment-naive, primary breast cancers (PBCs) (n = 45) and matched PBC and metastatic breast cancers (MBC) (n = 26). Seventy-eight percent of untreated PBCs contained PD-L1+ TILs, but only 21% had PD-L1+ carcinoma cells. Carcinoma PD-L1 expression localized to the tumor invasive front and was associated with high tumor grade (P =.04). Eighty-nine percent of PD-L1+ carcinomas contained brisk TIL infiltrates, compared to only 24% of PD-L1- carcinomas; this included CD3+ (P =.02), CD4+ (P =.04), CD8+ (P =.002), and FoxP3+ T cells (P =.02). PD-L1+ PBCs were more likely to contain PD-L1+ TIL than PD-L1- PBCs (P =.04). Peripheral lymphoid aggregates were present in 100% of PD-L1+ compared to 41% of PD-L1- PBC (P + PBC developed distant recurrence, compared to 15% of patients with PD-L1- PBC. For the matched PBC and MBC cohort, 2 patients (8%) had PD-L1+ tumors, with 1 case concordant and 1 case discordant for carcinoma PD-L1 expression in the PBC and MBC. Our data support PD-L1 expression by tumor cells as a biomarker of active breast tumor immunity and programmed death 1 blockade as a therapeutic strategy for breast cancer.

KW - Metastatic breast cancer

KW - PD-L1

KW - Primary breast cancer

KW - Tumor infiltrating lymphocytes

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=84951856362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951856362&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2015.09.003

DO - 10.1016/j.humpath.2015.09.003

M3 - Article

C2 - 26527522

AN - SCOPUS:84951856362

VL - 47

SP - 52

EP - 63

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 1

ER -